LH:NYE-Laboratory Corporation of America Holdings (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 236.37

Change

+3.72 (+1.60)%

Market Cap

USD 21.18B

Volume

0.78M

Analyst Target

USD 228.47
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs). In addition, the company offers online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; online applications for providers, MCOs, and accountable care organizations; specimen collection services; and drug development, medical device, and companion diagnostic development solutions, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governments, physician, large provider organizations, other healthcare providers, hospitals and health systems, patients and consumers, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was founded in 1995 is headquartered in Burlington, North Carolina.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-02 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

+4.77 (+2.38%)

USD 151.57B
A Agilent Technologies Inc

+1.94 (+1.70%)

USD 36.12B
IQV IQVIA Holdings Inc

+3.13 (+1.83%)

USD 33.79B
DGX Quest Diagnostics Incorporated

-1.32 (-0.78%)

USD 18.88B
CRL Charles River Laboratories

+3.29 (+2.25%)

USD 9.00B
QGEN Qiagen NV

+0.52 (+1.32%)

USD 8.30B
ENZ Enzo Biochem Inc

-0.01 (-2.21%)

USD 0.03B
TMO Thermo Fisher Scientific Inc

+6.09 (+1.26%)

N/A
WAT Waters Corporation

+6.64 (+1.87%)

N/A
MTD Mettler-Toledo International I..

+16.12 (+1.39%)

N/A

ETFs Containing LH

CAMX Cambiar Aggressive Value .. 4.33 % 0.00 %

+0.19 (+0.26%)

USD 0.06B
EDOC:LSE Global X Telemedicine & D.. 4.29 % 0.00 %

+0.02 (+0.26%)

USD 4.95M
EDOG:LSE Global X Telemedicine & D.. 4.29 % 0.00 %

N/A

USD 0.33M
DDOC:F Global X Telemedicine & D.. 4.23 % 0.00 %

+0.01 (+0.26%)

N/A
EDOC:SW Global X Telemedicine & D.. 3.97 % 0.00 %

+0.02 (+0.26%)

N/A
IHF iShares U.S. Healthcare P.. 0.00 % 0.43 %

+0.12 (+0.26%)

N/A
BVNSC 0.00 % 0.00 %

N/A

N/A
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 0.04B
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

-0.01 (0.26%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.07% 92% A 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.07% 92% A 72% C
Trailing 12 Months  
Capital Gain 11.37% 92% A 79% B-
Dividend Return 1.02% 71% C- 21% F
Total Return 12.39% 92% A 76% C+
Trailing 5 Years  
Capital Gain 142.82% 100% F 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 142.82% 91% A- 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 12.17% 92% A 71% C-
Dividend Return 12.70% 92% A 67% D+
Total Return 0.53% 57% F 13% F
Risk Return Profile  
Volatility (Standard Deviation) 40.12% 17% F 23% F
Risk Adjusted Return 31.66% 50% F 46% F
Market Capitalization 21.18B 63% D 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector